BRIEF-UniCredit Renews Partnership With Worldline For Open Banking
https://www.reuters.com/article/brief-unicredit-renews-partnership-with/brief-unicredit-renews-partnership-with-worldline-for-open-banking-idUSFWN2WH00W
https://www.reuters.com/article/brief-unicredit-renews-partnership-with/brief-unicredit-renews-partnership-with-worldline-for-open-banking-idUSFWN2WH00W
Apr 19th, 2022 - April 19 (Reuters) - UniCredit SpA: * HAS RENEWED PARTNERSHIP WITH WORLDLINE FOR OPEN BANKING THIRD PARTY PROVIDER (TPP) SERVICE * PARTNERSHIP HAS BEEN EXTENDED FOR ANOTHER TWO YEARS Further company coverage: (Gdansk newsroom)
BRIEF-GSK Says Daprodustat Application Accepted For Review By FDA
https://www.reuters.com/article/brief-gsk-says-daprodustat-application-a/brief-gsk-says-daprodustat-application-accepted-for-review-by-fda-idUSTUC8SYWX9
https://www.reuters.com/article/brief-gsk-says-daprodustat-application-a/brief-gsk-says-daprodustat-application-accepted-for-review-by-fda-idUSTUC8SYWX9
Apr 19th, 2022 - April 19 (Reuters) - GlaxoSmithKline PLC: * GLAXOSMITHKLINE PLC - DAPRODUSTAT APPLICATION ACCEPTED FOR REVIEW BY FDA * GSK - DAPRODUSTAT IS CURRENTLY APPROVED IN JAPAN AS DUVROQ FOR PATIENTS WITH RENAL ANAEMIA * GSK - US FDA REGULATORY SUBMISSION ACCEPTANCE IS THIRD MAJOR REGULATORY MILESTONE FOR DAPRODUSTAT * GSK - FDA HAS ASSIGNED A PRESCRIPTION DRUG USER FEE ACT (PDUFA) ACTION DATE OF 1 FEBR...
BRIEF-Astrazeneca Says Enhertu Granted Priority Review For Her2m NSCLC
https://www.reuters.com/article/brief-astrazeneca-says-enhertu-granted-p/brief-astrazeneca-says-enhertu-granted-priority-review-for-her2m-nsclc-idUSASM000823
https://www.reuters.com/article/brief-astrazeneca-says-enhertu-granted-p/brief-astrazeneca-says-enhertu-granted-priority-review-for-her2m-nsclc-idUSASM000823
Apr 19th, 2022 - April 19 (Reuters) - AstraZeneca PLC: * ASTRAZENECA PLC - ENHERTU GRANTED PRIORITY REVIEW FOR HER2M NSCLC Source text for Eikon: Further company coverage:
BRIEF-American Airlines Says Face Masks Will No Longer Be Required For Customers And Team Members At U.S. Airports And On Domestic Flights
https://www.reuters.com/article/brief-american-airlines-says-face-masks/brief-american-airlines-says-face-masks-will-no-longer-be-required-for-customers-and-team-members-at-u-s-airports-and-on-domestic-flights-idUSFWN2WH000
https://www.reuters.com/article/brief-american-airlines-says-face-masks/brief-american-airlines-says-face-masks-will-no-longer-be-required-for-customers-and-team-members-at-u-s-airports-and-on-domestic-flights-idUSFWN2WH000
Apr 19th, 2022 - April 18 (Reuters) - American Airlines Group Inc: * AMERICAN AIRLINES SAYS FACE MASKS WILL NO LONGER BE REQUIRED FOR CUSTOMERS AND TEAM MEMBERS AT U.S. AIRPORTS AND ON DOMESTIC FLIGHTS Further company coverage:
BRIEF-Reliance Is In Early Stages Of Exploring Feasibility Of Offer For Boots Chain - Bloomberg Quint Citing Bloomberg
https://www.reuters.com/article/brief-reliance-is-in-early-stages-of-exp/brief-reliance-is-in-early-stages-of-exploring-feasibility-of-offer-for-boots-chain-bloomberg-quint-citing-bloomberg-idUSFWN2WB17B
https://www.reuters.com/article/brief-reliance-is-in-early-stages-of-exp/brief-reliance-is-in-early-stages-of-exploring-feasibility-of-offer-for-boots-chain-bloomberg-quint-citing-bloomberg-idUSFWN2WB17B
Apr 13th, 2022 - April 13 (Reuters) - Reliance Industries Ltd: * RELIANCE IS IN EARLY STAGES OF EXPLORING FEASIBILITY OF OFFER FOR BOOTS CHAIN - BLOOMBERG QUINT CITING BLOOMBERG * BOOTS COULD BE VALUED AT AS MUCH AS $9.1 BILLION IN A SALE - BLOOMBERG QUINT CITING BLOOMBERG Source text for Eikon: Further company coverage:
BRIEF-Unicredit Shareholders Approve With 73.29% Of Votes 2022 Group Remuneration Policy
https://www.reuters.com/article/brief-unicredit-shareholders-approve-wit/brief-unicredit-shareholders-approve-with-73-29-of-votes-2022-group-remuneration-policy-idUSFWN2W60GA
https://www.reuters.com/article/brief-unicredit-shareholders-approve-wit/brief-unicredit-shareholders-approve-with-73-29-of-votes-2022-group-remuneration-policy-idUSFWN2W60GA
Apr 8th, 2022 - April 8 (Reuters) - UniCredit SpA: * SHAREHOLDERS APPROVE WITH 73.29% OF VOTES GROUP 2022 REMUNERATION POLICY Further company coverage: (Reporting by Gdansk Newsroom)
BRIEF-Medicare Officially Limits Coverage Of Aduhelm To Patients In Clinical Trials- NYT
https://www.reuters.com/article/brief-medicare-officially-limits-coverag/brief-medicare-officially-limits-coverage-of-aduhelm-to-patients-in-clinical-trials-nyt-idUSFWN2W51KK
https://www.reuters.com/article/brief-medicare-officially-limits-coverag/brief-medicare-officially-limits-coverage-of-aduhelm-to-patients-in-clinical-trials-nyt-idUSFWN2W51KK
Apr 7th, 2022 - April 7 (Reuters) - Biogen Inc: * MEDICARE OFFICIALLY LIMITS COVERAGE OF ADUHELM TO PATIENTS IN CLINICAL TRIALS- NYT * MEDICARE OFFICIALS CITED DATA SHOWING THE NEW ALZHEIMER’S DRUG HAS SERIOUS SAFETY RISKS AND MAY NOT HELP PATIENTS - NYT Source text for Eikon: Further company coverage:
BRIEF-Airbus Tells UK Court Boeing 737 MAX Has "Comparable If Not Better Range" Vs. A321NEO
https://www.reuters.com/article/brief-airbus-tells-uk-court-boeing-737-m/brief-airbus-tells-uk-court-boeing-737-max-has-comparable-if-not-better-range-vs-a321neo-idUSS8N2UL0GC
https://www.reuters.com/article/brief-airbus-tells-uk-court-boeing-737-m/brief-airbus-tells-uk-court-boeing-737-max-has-comparable-if-not-better-range-vs-a321neo-idUSS8N2UL0GC
Apr 7th, 2022 - April 7 (Reuters) - Airbus: * AIRBUS TELLS UK COURT BOEING 737 MAX HAS “COMPARABLE IF NOT BETTER RANGE” VERSUS A321NEO Further company coverage:
BRIEF-Australia's TGA Says Got Application For Increased Dose Of GSK's COVID-19 Treatment For BA.2 Omicron Sublineage
https://www.reuters.com/article/brief-australias-tga-says-got-applicatio/brief-australias-tga-says-got-application-for-increased-dose-of-gsks-covid-19-treatment-for-ba-2-omicron-sublineage-idUSFWN2W502T
https://www.reuters.com/article/brief-australias-tga-says-got-applicatio/brief-australias-tga-says-got-application-for-increased-dose-of-gsks-covid-19-treatment-for-ba-2-omicron-sublineage-idUSFWN2W502T
Apr 7th, 2022 - April 7 (Reuters) - Australia’s Therapeutic Goods Administration: * GOT APPLICATION FOR INCREASED DOSE OF GLAXOSMITHKLINE’S COVID-19 TREATMENT SOTROVIMAB (XEVUDY) FOR BA.2 OMICRON SUBLINEAGE * HIGHER DOSE WILL BE CONSIDERED FOR TREATMENT OF PATIENTS SUSPECTED TO HAVE INFECTION CAUSED BY OMICRON BA.2 SUBVARIANT * GSK SUBMITTED DATA TO TGA TO SUPPORT PROPOSED USE OF SINGLE 1000 MG DOSE OF SOTROVI...
BRIEF-New Large-Scale Observational Study Shows Covid-19 Could Create Vulnerability To Shingles For People Age 50+
https://www.reuters.com/article/brief-new-large-scale-observational-stud/brief-new-large-scale-observational-study-shows-covid-19-could-create-vulnerability-to-shingles-for-people-age-50-idUSFWN2W418U
https://www.reuters.com/article/brief-new-large-scale-observational-stud/brief-new-large-scale-observational-study-shows-covid-19-could-create-vulnerability-to-shingles-for-people-age-50-idUSFWN2W418U
Apr 6th, 2022 - April 6 (Reuters) - GlaxoSmithKline PLC: * NEW LARGE-SCALE OBSERVATIONAL STUDY SHOWS COVID-19 COULD CREATE VULNERABILITY TO SHINGLES FOR PEOPLE AGE 50+ Source text for Eikon: Further company coverage:
BRIEF-U.S. SEC Rules Against Amazon In Dispute With Investors Over Tax Transparency - FT
https://www.reuters.com/article/brief-us-sec-rules-against-amazon-in-dis/brief-u-s-sec-rules-against-amazon-in-dispute-with-investors-over-tax-transparency-ft-idUSFWN2W317X
https://www.reuters.com/article/brief-us-sec-rules-against-amazon-in-dis/brief-u-s-sec-rules-against-amazon-in-dispute-with-investors-over-tax-transparency-ft-idUSFWN2W317X
Apr 6th, 2022 - April 6 (Reuters) - * U.S. SEC RULES AGAINST AMAZON IN DISPUTE WITH INVESTORS OVER TAX TRANSPARENCY - FT * U.S. SEC DECIDES ISSUE OF AMAZON’S DISCLOSURE CAN BE PUT TO SHAREHOLDER VOTE AFTER INSTITUTIONAL PRESSURE - FT Further company coverage:
BRIEF-Unicredit Grants Sustainable Future Loan Of EUR 2 Mln To Errebi Marmi
https://www.reuters.com/article/brief-unicredit-grants-sustainable-futur/brief-unicredit-grants-sustainable-future-loan-of-eur-2-mln-to-errebi-marmi-idUSFWN2W406O
https://www.reuters.com/article/brief-unicredit-grants-sustainable-futur/brief-unicredit-grants-sustainable-future-loan-of-eur-2-mln-to-errebi-marmi-idUSFWN2W406O
Apr 6th, 2022 - April 6 (Reuters) - UniCredit SpA: * PROVIDES A SUSTAINABLE FUTURE LOAN OF EUR 2 MILLION IN FAVOR OF ERREBI MARMI SRL * LOAN IS AIMED AT SUPPORTING CARRARA-BASED COMPANY’S INVESTMENT PLAN * LOAN IS SUBJECT TO ACHIEVEMENT OF PRE-DETERMINED SUSTAINABILITY TARGETS Further company coverage: (Reporting by Gdansk Newsroom)
BRIEF-GSK Says From Q1 2022 Results Co Will Report Results Under Three Segments
https://www.reuters.com/article/brief-gsk-says-from-q1-2022-results-co-w/brief-gsk-says-from-q1-2022-results-co-will-report-results-under-three-segments-idUSTUC1TKQPM
https://www.reuters.com/article/brief-gsk-says-from-q1-2022-results-co-w/brief-gsk-says-from-q1-2022-results-co-will-report-results-under-three-segments-idUSTUC1TKQPM
Apr 1st, 2022 - April 1 (Reuters) - GlaxoSmithKline PLC: * GLAXOSMITHKLINE PLC - GSK - SEGMENT AND PRODUCT SALES REPORTING CHANGES * GSK: FROM Q1 2022 RESULTS GSK WILL REPORT RESULTS UNDER THREE SEGMENTS * GSK - CONSUMER HEALTHCARE SEGMENT WILL BE REPORTED AS A “CONTINUING OPERATION” UNTIL SUCH TIME AS FORMAL CRITERIA FOR TREATING IT OTHERWISE * GSK - SALES OF BRANDS DIVESTED IN Q1 2021 WILL NOT BE REPORTED IN...
BRIEF-Unicredit Sells Yapi Stake, Positive Mid-High Single Digit Impact On CET1 In Q2
https://www.reuters.com/article/brief-unicredit-sells-yapi-stake-positiv/brief-unicredit-sells-yapi-stake-positive-mid-high-single-digit-impact-on-cet1-in-q2-idUSFWN2VZ0E6
https://www.reuters.com/article/brief-unicredit-sells-yapi-stake-positiv/brief-unicredit-sells-yapi-stake-positive-mid-high-single-digit-impact-on-cet1-in-q2-idUSFWN2VZ0E6
Apr 1st, 2022 - April 1 (Reuters) - UniCredit SpA: * COMPLETES SALE OF ITS STAKE CORRESPONDING TO 18% OF ISSUED SHARE CAPITAL OF YAPI VE KREDI BANKASI A.Ş. (YKB) TO KOC HOLDING A.S * CLOSING OF TRANSACTION IS EXPECTED TO HAVE A MID-HIGH SINGLE DIGIT POSITIVE IMPACT ON UNICREDIT CONSOLIDATED CET1 RATIO, IN Q2 2022 * FOLLOWING TRANSACTION, UNICREDIT S.P.A. CEASED TO BE A SHAREHOLDER OF YKB Further company covera...
BRIEF-EMA Says Looking At Extension Of Novavax COVID Shot For Adolescents
https://www.reuters.com/article/brief-ema-says-looking-at-extension-of-n/brief-ema-says-looking-at-extension-of-novavax-covid-shot-for-adolescents-idUSFWN2VX12Q
https://www.reuters.com/article/brief-ema-says-looking-at-extension-of-n/brief-ema-says-looking-at-extension-of-novavax-covid-shot-for-adolescents-idUSFWN2VX12Q
Mar 30th, 2022 - March 30 (Reuters) - European Medicines Agency (EMA): * STARTED EVALUATING AN APPLICATION TO EXTEND THE USE OF NOVAVAX’S COVID-19 VACCINE, NUVAXOVID, TO ADOLESCENTS AGED 12 TO 17 Further company coverage:
BRIEF-GSK-Sanofi To Submit Final Files Of COVID-19 Shot To U.S. FDA In Coming Weeks - Spokesperson
https://www.reuters.com/article/brief-gsk-sanofi-to-submit-final-files-o/brief-gsk-sanofi-to-submit-final-files-of-covid-19-shot-to-u-s-fda-in-coming-weeks-spokesperson-idUSFWN2VX0ZB
https://www.reuters.com/article/brief-gsk-sanofi-to-submit-final-files-o/brief-gsk-sanofi-to-submit-final-files-of-covid-19-shot-to-u-s-fda-in-coming-weeks-spokesperson-idUSFWN2VX0ZB
Mar 30th, 2022 - March 30 (Reuters) - GlaxoSmithKline PLC: * GSK SPOKESPERSON SAYS CO, SANOFI WILL SUBMIT FINAL FILES OF THEIR COVID-19 SHOT TO U.S. FDA AND OTHER AGENCIES IN COUNTRIES WITH APAS IN COMING WEEKS Further company coverage:
BRIEF-EMA Says CHMP Started Evaluating Application For Conditional Marketing Authorisation Of Sanofi Pasteur's COVID-19 Vaccine, Vidprevtyn
https://www.reuters.com/article/brief-ema-says-chmp-started-evaluating-a/brief-ema-says-chmp-started-evaluating-application-for-conditional-marketing-authorisation-of-sanofi-pasteurs-covid-19-vaccine-vidprevtyn-idUSFWN2VX0QM
https://www.reuters.com/article/brief-ema-says-chmp-started-evaluating-a/brief-ema-says-chmp-started-evaluating-application-for-conditional-marketing-authorisation-of-sanofi-pasteurs-covid-19-vaccine-vidprevtyn-idUSFWN2VX0QM
Mar 30th, 2022 - March 30 (Reuters) - European Medicines Agency: * EMA: EMA’S CHMP STARTED EVALUATING THE APPLICATION FOR A CONDITIONAL MARKETING AUTHORISATION OF SANOFI PASTEUR’S COVID-19 VACCINE, VIDPREVTYN: 30/03/2022 * EMA: EMA’S CHMP STARTED EVALUATING THE APPLICATION FOR A CONDITIONAL MARKETING AUTHORISATION OF SANOFI PASTEUR’S COVID-19 VACCINE, VIDPREVTYN: 30/03/2022
BRIEF-Unitedhealth To Buy Home-Health Firm LHC Group For $5.4 Billion - WSJ
https://www.reuters.com/article/brief-unitedhealth-to-buy-home-health-fi/brief-unitedhealth-to-buy-home-health-firm-lhc-group-for-5-4-billion-wsj-idUSFWN2VW0F7
https://www.reuters.com/article/brief-unitedhealth-to-buy-home-health-fi/brief-unitedhealth-to-buy-home-health-firm-lhc-group-for-5-4-billion-wsj-idUSFWN2VW0F7
Mar 29th, 2022 - March 29 (Reuters) - * UNITEDHEALTH TO BUY HOME-HEALTH FIRM LHC GROUP FOR $5.4 BILLION - WSJ Further company coverage:
BRIEF- EMA Recommends Authorisation Of Evusheld In Adults And Adolescents From 12 Years Of Age
https://www.reuters.com/article/brief-ema-recommends-authorisation-of-ev/brief-ema-recommends-authorisation-of-evusheld-in-adults-and-adolescents-from-12-years-of-age-idUSFWN2VR0ZD
https://www.reuters.com/article/brief-ema-recommends-authorisation-of-ev/brief-ema-recommends-authorisation-of-evusheld-in-adults-and-adolescents-from-12-years-of-age-idUSFWN2VR0ZD
Mar 24th, 2022 - March 24 (Reuters) - European Medicines Agency (EMA: * EMA: EMA RECOMMENDS AUTHORISATION OF COVID-19 MEDICINE EVUSHELD: 24/03/2022 * EMA: RECOMMENDS AUTHORISATION FOR ASTRAZENECA’S EVUSHELD FOR PREVENTION OF COVID-19 IN ADULTS AND ADOLESCENTS FROM 12 YEARS OF AGE * EMA: SAFETY PROFILE OF EVUSHELD FAVOURABLE, SIDE EFFECTS GENERALLY MILD, SMALL NUMBER OF PEOPLE REPORTING REACTIONS AT INJECTION SI...
BRIEF-Sanofi Says Stopped New Spending Not Related To Supply Of Our Essential, Life-Changing Medicines And Vaccines In Russia, As Well As In Belarus - Tweet
https://www.reuters.com/article/brief-sanofi-says-stopped-new-spending-n/brief-sanofi-says-stopped-new-spending-not-related-to-supply-of-our-essential-life-changing-medicines-and-vaccines-in-russia-as-well-as-in-belarus-tweet-idUSFWN2VQ0TO
https://www.reuters.com/article/brief-sanofi-says-stopped-new-spending-n/brief-sanofi-says-stopped-new-spending-not-related-to-supply-of-our-essential-life-changing-medicines-and-vaccines-in-russia-as-well-as-in-belarus-tweet-idUSFWN2VQ0TO
Mar 23rd, 2022 - March 23 (Reuters) - * SANOFI SAYS STOPPED NEW SPENDING NOT RELATED TO SUPPLY OF OUR ESSENTIAL, LIFE-CHANGING MEDICINES AND VACCINES IN RUSSIA, AS WELL AS IN BELARUS - TWEET Further company coverage:
